Inactive Instrument

IntelliPharmaCeutics International Inc. Stock OTC Bulletin Board

CA4581733090

Valuation: IntelliPharmaCeutics International Inc.

Market Cap	1.28M 1.12M 1.04M 958K 1.8M 124M 1.83M 12.42M 4.86M 60.5M 4.81M 4.71M 209M	P/E 2021	-0.4x	P/E 2022	-0.91x
Enterprise Value	3.52M 3.09M 2.87M 2.63M 4.96M 340M 5.04M 34.14M 13.36M 166M 13.23M 12.94M 575M	EV / Sales 2021	-	EV / Sales 2022	74x
Free-Float	98.24%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Managers and Directors: IntelliPharmaCeutics International Inc.

Manager	Title	Age	Since
Amina Odidi DFI	Director of Finance/CFO	-	-
Fazayill Shaideen AUD	Comptroller/Controller/Auditor	-	2007-03-31
Christian Akyempon PRN	Corporate Officer/Principal	-	2014-01-31

Director	Title	Age	Since
Amina Odidi BRD	Director/Board Member	-	2004-08-31

More insiders

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Companyâ€™s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTELLIPHARMACEUTICS INTERNATIONAL INC.	+6.06%	+14.94%	-	-	1.52M
ELI LILLY AND COMPANY	-1.05%	+0.91%	+52.59%	+151.71%	1,048B
JOHNSON & JOHNSON	+2.00%	+0.70%	+55.53%	+50.20%	603B
ABBVIE INC.	-1.09%	+3.48%	+37.03%	+76.22%	452B
ROCHE HOLDING AG	-0.42%	+1.65%	+30.05%	+21.05%	327B
NOVARTIS AG	-0.16%	+2.39%	+36.91%	+37.33%	283B
ASTRAZENECA PLC	+1.68%	+2.73%	+24.14%	+17.94%	259B
NOVO NORDISK A/S	-1.40%	-0.06%	-22.24%	-42.39%	219B
AMGEN INC.	-0.05%	+3.04%	+23.72%	+55.89%	198B
GILEAD SCIENCES, INC.	+0.05%	+0.23%	+20.37%	+61.63%	162B
Average	+0.61%	+1.74%	+28.68%	+47.73%	394.63B
Weighted average by Cap.	-0.01%	+1.69%	+38.02%	+72.54%

	2021	2022
Net sales	-	65.73K 57.59K 53.46K 49.13K 92.58K 6.34M 93.94K 637K 249K 3.1M 247K 241K 10.72M
Net income	-5.15M -4.51M -4.19M -3.85M -7.25M -496M -7.35M -49.86M -19.51M -243M -19.31M -18.9M -839M	-2.89M -2.53M -2.35M -2.16M -4.07M -279M -4.13M -28.03M -10.97M -137M -10.86M -10.62M -472M
Net Debt	1.15M 1M 932K 856K 1.61M 111M 1.64M 11.1M 4.34M 54.08M 4.3M 4.21M 187M	2.24M 1.96M 1.82M 1.68M 3.16M 216M 3.2M 21.73M 8.5M 106M 8.42M 8.24M 366M

IntelliPharmaCeutics International Inc. Stock OTC Bulletin Board

Stocks

CA4581733090

Pharmaceuticals

Valuation: IntelliPharmaCeutics International Inc.

Quotes and Performance

Managers and Directors: IntelliPharmaCeutics International Inc.

Other Pharmaceuticals

Financials

Company Profile